UK digital health company Aide Health has launched its first US programme through a new partnership with Temple Health, targeting one of healthcare’s fastest growing and most costly conditions — type 2 diabetes.

The collaboration, part of the 2026 Clinical Care Innovation Grant programme funded by Independence Blue Cross (IBX), will support the development of new app support models designed to improve patient outcomes, reduce barriers to care, and lower costs.

The partnership marks a significant milestone in Aide Health’s international expansion, building on proven success within the NHS.

The new programme, My Health Aide, will introduce Aide Health’s conversational AI platform designed to support patients outside traditional clinical settings.

Through short, daily interactions, the tool helps patients adhere to their medication, monitor their condition, and access trusted health information on demand. Clinicians, meanwhile, receive real-time data insights, enabling earlier intervention and more personalised care.